JP2012517017A - Ｊｃポリオーマウイルスの検出のための方法 - Google Patents

Ｊｃポリオーマウイルスの検出のための方法 Download PDF

Info

Publication number
JP2012517017A
JP2012517017A JP2011549163A JP2011549163A JP2012517017A JP 2012517017 A JP2012517017 A JP 2012517017A JP 2011549163 A JP2011549163 A JP 2011549163A JP 2011549163 A JP2011549163 A JP 2011549163A JP 2012517017 A JP2012517017 A JP 2012517017A
Authority
JP
Japan
Prior art keywords
jcv
pml
subject
variant
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2011549163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012517017A5 (https=
Inventor
レオニド ゴレリク，
アレクセイ ルゴフスコイ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Inc
Biogen Idec Inc
Biogen Idec MA Inc
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42542341&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2012517017(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc, Biogen Idec Inc, Biogen Idec MA Inc, Biogen MA Inc filed Critical Biogen Inc
Publication of JP2012517017A publication Critical patent/JP2012517017A/ja
Publication of JP2012517017A5 publication Critical patent/JP2012517017A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2011549163A 2009-02-05 2010-02-05 Ｊｃポリオーマウイルスの検出のための方法 Ceased JP2012517017A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15031009P 2009-02-05 2009-02-05
US61/150,310 2009-02-05
PCT/US2010/000342 WO2010090757A1 (en) 2009-02-05 2010-02-05 Methods for the detection of jc polyoma virus

Publications (2)

Publication Number Publication Date
JP2012517017A true JP2012517017A (ja) 2012-07-26
JP2012517017A5 JP2012517017A5 (https=) 2013-03-14

Family

ID=42542341

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011549163A Ceased JP2012517017A (ja) 2009-02-05 2010-02-05 Ｊｃポリオーマウイルスの検出のための方法

Country Status (11)

Country Link
US (2) US20130101985A9 (https=)
EP (1) EP2394163B1 (https=)
JP (1) JP2012517017A (https=)
CN (2) CN102369436B (https=)
AU (1) AU2010210979B2 (https=)
BR (1) BRPI1016273A2 (https=)
CA (1) CA2751364C (https=)
ES (1) ES2842425T3 (https=)
NZ (1) NZ594973A (https=)
SG (2) SG173201A1 (https=)
WO (1) WO2010090757A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016513072A (ja) * 2012-12-31 2016-05-12 ニューリミューン ホールディング エイジー ポリオーマウイルス関連疾患の治療および防止のための組換えヒト抗体

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207141A1 (en) 2006-02-28 2007-09-06 Ivan Lieberburg Methods of treating inflammatory and autoimmune diseases with natalizumab
MX2008011176A (es) 2006-03-03 2008-09-10 Elan Pharm Inc Metodos para tratar padecimientos inflamatorios y autoinmunes con natalizumab.
CN102369436B (zh) 2009-02-05 2014-10-22 生物基因Idecma公司 用于检测jc多瘤病毒的方法
CN102906278A (zh) 2010-01-11 2013-01-30 比奥根艾迪克Ma公司 用于jc病毒抗体的测定
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
DK2715352T3 (da) 2011-05-31 2019-05-20 Biogen Ma Inc Fremgangsmåde til vurdering af risiko for pml
DK2734544T3 (da) 2011-07-18 2021-03-15 Us Health Fremgangsmåder og sammensætninger til hæmning af polyomavirus-associeret patologi
EP2548567A1 (en) 2011-07-22 2013-01-23 Universitätsklinikum Hamburg-Eppendorf Polyoma virus JC peptides and proteins in vaccination and diagnostic applications
EP2636746A1 (en) * 2012-03-06 2013-09-11 Life Science Inkubator A novel drug delivery system based on JCV-VLP
WO2013142300A2 (en) * 2012-03-20 2013-09-26 Biogen Idec Ma Inc. Jcv neutralizing antibodies
ES2731757T3 (es) 2012-03-20 2019-11-18 Biogen Ma Inc Anticuerpos neutralizantes de JCV
WO2013192100A1 (en) 2012-06-18 2013-12-27 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods and compositions for detecting jc virus
SI2774991T1 (en) * 2013-03-06 2018-04-30 Life Science Inkubator Betriebs Gmbh & Co. Kg A system for supplying a medicament for use in the treatment or diagnosis of neurological disorders
EP2971119A4 (en) * 2013-03-15 2016-11-02 Biogen Ma Inc MELT ANALYSIS ASSAY HIGHLY RESOLVED TO DETECT VIRAL DNA
WO2014193804A1 (en) 2013-05-28 2014-12-04 Biogen Idec Ma Inc. Method of assessing risk of pml
WO2015095770A1 (en) 2013-12-20 2015-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic jc polyomavirus compositions and methods of use
US20200197544A1 (en) * 2017-04-26 2020-06-25 Biogen Ma Inc. Jcv imaging methods and compositions
CN112442553A (zh) * 2020-10-27 2021-03-05 深圳市罗湖区人民医院 一种用于JCPyV检测与分型的试剂盒及方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0967397A (ja) * 1995-06-23 1997-03-11 Eisai Co Ltd 抗ｊｃウイルス抗体
JP2003061693A (ja) * 2001-06-28 2003-03-04 Jenapharm Gmbh & Co Kg ウイルス様粒子、その製造方法およびその使用
JP2007197441A (ja) * 1995-11-22 2007-08-09 Schering Ag ウイルス様粒子、その製造方法、その使用、それを含有する調剤学的組成物、ｊｃｖに対する特異的抗体を免疫学的に測定する方法及び試験キット

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125517A0 (en) 1996-01-26 1999-03-12 Univ California Polymeric film assay and method for direct colorimetric detection of analytes
JP4840792B2 (ja) 2001-11-22 2011-12-21 独立行政法人科学技術振興機構 ＪＣウイルスａｇｎｏを対象としたＰＭＬの治療
US20080131928A1 (en) 2004-07-01 2008-06-05 Hiroshi Handa Viral Particle-Like Construct and Method of Forming the Same Under Physiological Conditions
JP4757103B2 (ja) 2005-06-13 2011-08-24 学校法人関西文理総合学園 試料中のウイルスを検出する方法およびシステム
US7468186B2 (en) 2005-07-22 2008-12-23 City Of Hope Polyomavirus cellular epitopes and uses therefor
US20070134652A1 (en) 2005-11-09 2007-06-14 Primera Biosystems, Inc. Multiplexed quantitative detection of pathogens
US7769230B2 (en) * 2006-11-30 2010-08-03 Eastman Kodak Company Producing low resolution images
WO2008077511A1 (en) 2006-12-22 2008-07-03 Karolinska Institutet Innovations Ab Human polyomavirus and methods of diagnosis and treatment
JP2008249433A (ja) 2007-03-29 2008-10-16 Kansai Bunri Sogo Gakuen 被験物質に対するプローブの結合親和性を測定する方法及びその利用
US20110118340A1 (en) 2008-02-08 2011-05-19 Muthiah Manoharan Delivery of rnai constructs to oligodendrocytes
CN102369436B (zh) 2009-02-05 2014-10-22 生物基因Idecma公司 用于检测jc多瘤病毒的方法
KR20140057296A (ko) 2011-07-29 2014-05-12 바이오겐 아이덱 엠에이 인코포레이티드 Jc 바이러스 dna의 검출 분석
AR095089A1 (es) 2013-01-30 2015-09-30 Biogen Idec Inc Ensayo de detección de adn de virus jc

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0967397A (ja) * 1995-06-23 1997-03-11 Eisai Co Ltd 抗ｊｃウイルス抗体
JP2007197441A (ja) * 1995-11-22 2007-08-09 Schering Ag ウイルス様粒子、その製造方法、その使用、それを含有する調剤学的組成物、ｊｃｖに対する特異的抗体を免疫学的に測定する方法及び試験キット
JP2003061693A (ja) * 2001-06-28 2003-03-04 Jenapharm Gmbh & Co Kg ウイルス様粒子、その製造方法およびその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6016020147; Ｚｈｅｎｇ　ＨＹ、外９名: 'Ｃｈａｒａｃｔｅｒｉｚａｔｉｏｎ　ｏｆ　ｔｈｅ　ＶＰ１　ｌｏｏｐ　ｍｕｔａｔｉｏｎｓ　ｗｉｄｅｓｐｒｅａｄ　ａｍｏｎｇ　ＪＣ　ｐｏｌｙｏｍａｖｉｒｕｓ　ｉｓｏｌａｔｅｓ　ａｓｓｏｃｉａｔｅｄ　ｗｉｔｈ' Ｂｉｏｃｈｅｍ　Ｂｉｏｐｈｙｓ　Ｒｅｓ　Ｃｏｍｍｕｎ． Ｖｏｌ．３３３，Ｎｏ．３, 200508, Ｐａｇｅ．９９６-１００２ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016513072A (ja) * 2012-12-31 2016-05-12 ニューリミューン ホールディング エイジー ポリオーマウイルス関連疾患の治療および防止のための組換えヒト抗体

Also Published As

Publication number Publication date
US20130101985A9 (en) 2013-04-25
WO2010090757A1 (en) 2010-08-12
EP2394163B1 (en) 2020-08-19
US9696307B2 (en) 2017-07-04
EP2394163A4 (en) 2012-08-01
CA2751364A1 (en) 2010-08-12
SG173201A1 (en) 2011-08-29
CN104316696A (zh) 2015-01-28
EP2394163A1 (en) 2011-12-14
AU2010210979A1 (en) 2011-09-22
US20150219651A1 (en) 2015-08-06
NZ594973A (en) 2012-05-25
SG2014009120A (en) 2014-03-28
CA2751364C (en) 2017-06-20
US20120258443A1 (en) 2012-10-11
CN102369436B (zh) 2014-10-22
BRPI1016273A2 (pt) 2020-12-01
CN102369436A (zh) 2012-03-07
ES2842425T3 (es) 2021-07-14
AU2010210979B2 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
US9696307B2 (en) Methods for the detection of JC polyoma virus
Zhang et al. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
Walls et al. Unexpected receptor functional mimicry elucidates activation of coronavirus fusion
Flyak et al. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2–MPER region
Ladner Mapping the epitopes of antibodies
JP6735005B2 (ja) グリピカンエピトープおよびその使用
CN104520318B (zh) 针对jc病毒的vp1蛋白的人单克隆抗体
Shang et al. NRP1 is a receptor for mammalian orthoreovirus engaged by distinct capsid subunits
WO2021209824A1 (en) Methods and products for serological analysis of sars-cov-2 infection
CN110914685A (zh) Rep蛋白作为蛋白质抗原用于诊断试验
Ssebyatika et al. Broadly neutralizing antibodies isolated from HEV convalescents confer protective effects in human liver-chimeric mice
Byrnes et al. A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 binding
Kallunki et al. Rational selection of the monoclonal α-synuclein antibody amlenetug (Lu AF82422) for the treatment of α-synucleinopathies
US20190107544A1 (en) Bk virus serology assessment of progressive multifocal leukoencephalopathy (pml) risk
Tortorici et al. Molecular basis of pathogenicity of the recently emerged FCoV-23 coronavirus
Wang et al. A subset of Memory B-derived antibody repertoire from 3-dose vaccinees is ultrapotent against diverse and highly transmissible SARS-CoV-2 variants, including Omicron
Wang et al. Molecular blueprints of the Langya virus attachment and fusion glycoproteins
US20240402174A1 (en) Methods for determining norovirus-reactive antibodies
US20240116994A1 (en) Peptides And Use Thereof For Diagnosing And Treating Antiphospholipid Syndrome
JP2024051908A (ja) コロナウイルス中和抗体
KR20240009996A (ko) 항노로바이러스 항체
KR20240009995A (ko) 항노로바이러스 항체
Bywaters Anti-Capsid Monoclonal Antibodies: Tools to Assess HPV Neutralization and Capsid Structure
Acton Immunoglobulins—Advances in Research and Application: 2013 Edition
Zhou et al. A protective broadly cross-reactive human antibody defines a conserved

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20131030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140131

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140325

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150414

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160201

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160318

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160601

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20161020